Patient characteristics, adverse events, and response to nivolumab treatment
| Patient 1 | Patient 2 | Patient 3 | |
|---|---|---|---|
| Age | 47 | 25 | 55 |
| Sex | Male | Male | Male |
| Prior therapies (no.) | 6 | 6 | 5 |
| Stem cell source | Matched-related | Matched-related | Haploidentical and umbilical cord blood |
| Conditioning regimen | Reduced intensity | Reduced intensity | Reduced intensity |
| T cell depleted graft | Yes | Yes | Yes |
| Prior GVHD | No | Chronic GVHD of gut | Chronic oral GVHD |
| Days to relapse following AlloHSCT (no.) | 181 | 2456 | 389 |
| Localization and size of relapse | Diffuse bone and splenic involvement | Multifocal adenopathy in mediastinum, retroperitoneum and pelvis. Largest lymph node 2.3 × 1.5 cm in mediastinum | Multifocal adenopathy in neck, chest, abdomen and pelvis. Largest lymph node 4.2 × 1.8 cm in right axilla |
| Prior DLI | No | Yes | No |
| Immune-related adverse events | Grade 2 Keratoconjunctivitis | Grade 3 Inflammatory polyarthritis and grade 2 keratoconjunctivitis | Grade 1 Rash |
| Response to nivolumab | Partial response | Partial response | Partial response |
| Duration of response | 6 Months+ | 10 Months+ | 14 Months+ |
| Donor CD3+ chimerism before and after treatment | 18 to 49% | Not available | Not available |